|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.21 USD | -17.11% |
|
-0.33% | -85.11% |
| 07:49pm | Sarepta shares slump after third patient death this year | RE |
| 07:49pm | Sarepta says 51-year-old male patient died in early stage study of SRP-9004 | RE |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
| 190.2Cr | 12.37% | 11.47% | 19.71% | 6.51% | -0.85x | ||
| 56Cr | -101.6% | -95.67% | -214.5% | -38.02% | 1.49x | ||
| Average | 123.11Cr | -44.61% | -42.1% | -97.39% | -15.75% | 0.32x | |
| Weighted average by Cap. | 117.06Cr | -49.75% | -46.93% | -107.95% | -17.76% | 0.42x |
- Stock Market
- Equities
- SRPT Stock
- Sector Sarepta Therapeutics, Inc.
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition